Another quiet day on the biotech news front, where the only real news of interest was the REGN earnings. The REGN miss and weak market not surprisingly led to a.
It was actually a quiet start to the week but there are a couple of points that I want to make and issues to put on the radar. 1. I.
Lots of good earnings and conference calls to go through. It is going to take a couple of days to sort through it all so I will try and focus.
While today seemed to have better trading action, the news was actually less interesting than Monday. There are a couple of notes but nothing quite significant. In fact, the most.
It was a relatively quiet day on the news front outside of the hep-C space where there as some news on both VRTX and GILD. Not much happening in the.
The news du jour today was SRPT and I want to focus today’s note entirely on it because there is a lot to talk about. In addition, I want to.
It is more of the same in that the market is a little quiet on news. I expected that there would be something interesting to talk about today but not.
Not a ton of news today, so this will be a little bit of a short update but some company specific news with CELG. Outside of that there was the.
Seemed like a slow news day as the markets pulled back to consolidate some of the recent moves. Biotechs were not immune to the move, although some clearly performed better.
There have been a couple days of biotech buying, especially it seems in the small cap antibiotic space. Outside of the general performance, there has been some significant news. All.